Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$36.29 0.38 (1.06%)
2/9/2010 4:02 PM

Sanofi-Aventis (ADR) (SNY)

CAPS Rating:
****

A global pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating SNY

Add Stock to Watchlist

What the Community Thinks

Sanofi-Aventis (ADR) At A Glance

Current Price: $36.29
Last Trade Time: 2/9/2010 4:02 PM
Open: $0.00
Previous Close: $35.91
Daily Range: $35.88 - $36.68
52-Week Range: $24.59 - $41.59
Volume: 1,187,058
Market Cap: $95.48B
P/E Ratio: 19.31
Compare Our Special Broker Offers!

Stock Trends

SNY VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

1

Sanofi-Aventis (ADR) (SNY)

Avatar brianpivar (92.49) Submitted: 12/03/09 1:37 AM

Great dividend yield, Cramer Recommendation, good fundamentals

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

Sanofi-Aventis (ADR) (SNY)

Avatar anton123 (< 20) Submitted: 6/25/09 10:37 AM

UBS’s Amusa has a “sell” rating on Sanofi and has a “buy” rating on Novo Nordisk A/S, which produces a rival diabetes treatment called Levemir.

“We have to be careful not to taint a medicine which helps many patients, but if Sanofi have data we should see it,” said Kevin Scotcher, an analyst at Lib...More

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 124 :   1 2 3 4 5 Next » Jump to page:

Recs

0

 (SNY)

Avatar Staka (98.79) Submitted: 12/06/09 6:48 AM : Outperform Start Price: $38.85 SNY Score: -3.26

Sanofi-Aventis received good news recently with the company gaining approval from the European Commission for its atrial fibrillation drug, Multaq.

The EU approval is based on clinical data including results from seven international, multi-center, randomized clinical trials involving more than 7,000 patients and including the landmark ATHENA trial. Initial product launches are scheduled to take place in the United Kingdom and Germany in January 2010.

Multaq is already approved in the U.S., Canada, Switzerland and Brazil.

Approval in the European Union should open up a huge market for Sanofi. According to the company, AF affects about 4.5 million people in the European Union. It increases the risk of stroke fivefold, worsens the prognosis of patients with cardiovascular risk factors, and doubles the risk of mortality.

Phase III results on Multaq showed that it, along with standard therapy, significantly reduced the risk of cardiovascular hospitalization or death by 24% compared to placebo. Multaq will contribute significantly to revenues and it could eventually achieve blockbuster status.

Category: IYBP

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (SNY)

Avatar brianpivar (92.49) Submitted: 12/03/09 1:37 AM : Outperform Start Price: $39.80 SNY Score: -4.94

Great dividend yield, Cramer Recommendation, good fundamentals

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SNY)

Avatar CoachBen (< 20) Submitted: 11/27/09 12:23 AM : Outperform Start Price: $37.69 SNY Score: -2.63

Solid financials. Balanced markets make is less vulnerable to fluctuations in US market. Finally, even without gang-buster success with the HIV vaccine, they have some great new products.

One such product is Multaq. Working in Cardiology, I see first hand how this medication is swooping in to take the place of the most widely used heart rhythm medicines. Study's show that it's equally as effective as the best one out there on the market (Amiodarone) without the major (and minor) side effects and without the drug interactions. It is safe in elderly populations and I expect to see its indications expanded.

Hopefully in 2010 it will become a tier two drug and when that happens usage is going to explode.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SNY)

Avatar mrmok (72.90) Submitted: 11/16/09 1:41 AM : Outperform Start Price: $38.53 SNY Score: -2.95

FC

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SNY)

Avatar germanjuggler (< 20) Submitted: 10/20/09 5:20 AM : Underperform Start Price: $39.13 SNY Score: 4.77

overvalued.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 124 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 15 of 15  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackJimCramer < 20 11/20/09 Outperform 3W $37.67-3.66%-2.02%-1.64
TrackDeutscheSec 89.68 11/17/09 Outperform NS $38.53-5.81%-2.86%-2.95
TrackJPMorgan 84.76 08/29/09 Outperform NS $35.11+3.36%+3.36% 0
TrackCitigroup 85.92 05/28/09 Outperform NS $31.37+15.68%+19.77%-4.08
TrackCreditSuiss 93.62 03/17/09 Outperform NS $25.67+41.39%+43.44%-2.06
TrackEdwardOwens 98.91 11/24/08 Outperform 1Y $26.09+39.09%+33.94%+5.16 Toggle the visibility of 60-Second Pitch and replies
TrackDodgeCox 90.73 09/30/07 Outperform NS $39.18-7.37%-26.38%+19.01 Toggle the visibility of 60-Second Pitch and replies
TrackBuffett 80.73 09/30/07 Outperform NS $39.18-7.37%-26.38%+19.01 Toggle the visibility of 60-Second Pitch and replies
TrackEveillard 93.31 09/30/07 Outperform NS $39.18-7.37%-26.38%+19.01 Toggle the visibility of 60-Second Pitch and replies
TrackNWQ < 20 09/30/07 Outperform NS $39.18-7.37%-26.38%+19.01 Toggle the visibility of 60-Second Pitch and replies
TrackBrandes < 20 09/30/07 Outperform NS $39.18-7.37%-26.38%+19.01 Toggle the visibility of 60-Second Pitch and replies
TrackHSBC 86.09 07/18/07 Outperform NS $39.49-8.10%-26.82%+18.72
TrackCharlesPayn 63.30 12/16/06 Outperform 3M $41.36-12.26%-20.05%+7.79
TrackBofASec 94.61 11/10/06 Outperform NS $38.22-5.06%-17.62%+12.56
TrackBearStearns 84.85 11/01/06 Underperform NS $38.62-6.04%-17.66%-11.63

Results 1 - 15 of 15  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD01 31ms